EPIRUS Biopharmaceuticals, Inc.
Not enough financial coverage to compute a composite score for EPRSQ. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Companyepirusbiopharma.com
EPIRUS Biopharmaceuticals, Inc. , a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases.
- CEO
- Jeff Kagy
- IPO
- 2005
- Employees
- 73
- HQ
- Boston, MA, US
Price Chart
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -14.11
- Avg Volume
- 0
Get TickerSpark's AI analysis on EPRSQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our EPRSQ Coverage
We haven't published any research on EPRSQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EPRSQ Report →